Genevieve Gauthier, MSc, serves as a senior director and Real-World Evidence (RWE) Scientist for Inflammation and Immunology at Pfizer.

About 1 in 3 patients diagnosed with vitiligo did not go on to receive treatment, data suggest.

Among treated patients, therapy duration was short, often just two to four months per line of treatment.

Children and adolescents were more likely to receive topical-only treatment, while systemic options were more common in adults.

 remains a chronic condition with limited standardized treatment approaches, and new real-world data are shedding light on just how inconsistent care can be.

 Q&A interview, Genevieve Gauthier, MSc, highlighted findings from a recent 

 study examining treatment patterns among nearly 25,000 patients with vitiligo, including how often individuals go untreated after diagnosis and how long they typically stay on therapy once their treatment begins.

Gauthier also explores how treatment approaches differ across age groups, why visible lesions may carry a heightened psychosocial burden, and what these real-world patterns reveal about unmet needs in vitiligo care. The following Q&A highlights Gauthier’s responses to 

: One of the biggest findings in your study was that many patients with vitiligo did not receive treatment during follow-up. Why do you think so many patients are going untreated, and what does that say about the current state of vitiligo care?

 Our study described what’s happening rather than the reasons behind individual treatment decisions, so I can’t speak in detail to the “why.” What makes this finding particularly meaningful is the context: these were patients who had been diagnosed, who had entered the healthcare system, and in many cases were diagnosed by a dermatologist (46.4%), and still a substantial share didn’t go on to treatment.

Additionally, among patients who were treated, therapy duration was relatively short, a median of roughly two to four months for first and second lines of therapy, and treatment sequences varied substantially from patient to patient. In totality, those findings suggest that current treatment approaches may not, in some vitiligo patients, be meeting patients' needs over the long term.

: You also found that treatment duration was often fairly short. What do you think is contributing to patients stopping or switching therapies so quickly in real-world practice?

We were not able to determine the specific reasons why patients discontinued or switched therapies as this information was not available in the databases we used for this study. However, when considered alongside the high variability observed in treatment sequences, these findings may suggest that some patients with vitiligo face limited long-term treatment options and a lack of standardized, sustained approaches to care.

In real-world clinical practice, these patterns could be influenced by multiple factors, including heterogeneity in patient response, tolerability considerations, challenges with long-term adherence, and the overall complexity of managing a chronic condition like vitiligo. That being said, additional studies would be warranted to better understand what is driving treatment discontinuation and switch in vitiligo patients and inform future research and development of durable treatment strategies.

: The face was the most commonly affected area in your analysis. How important is it for clinicians to consider the emotional and quality-of-life impact of vitiligo, especially when visible areas are involved?

 While we didn’t measure quality-of-life in our study, there is a substantial body of literature showing that vitiligo carries a significant psychosocial burden impacting patients’ quality of life. Studies have also demonstrated that patients with facial lesions have a higher psychosocial burden vs. those without facial lesions.

To me the fact that most patients in our study had visible lesions on the face underscores the need for clinicians to take a more holistic approach to vitiligo care – an approach that goes beyond clinical measures and fully considers the broader patient experience

: Your study showed some differences in treatment patterns between children and adults. Were there any age-related trends that surprised you, and how should dermatologists think about treating younger patients with vitiligo?

Results from our study showed that children and adolescents were more likely than adults to receive topical treatments, while systemic treatments, including oral corticosteroids, were more common in adults. As a first line, topical-only treatment was used in roughly 90% of children and 80% of adolescents, versus about 60% of adults. These findings weren’t surprising as they are consistent with evidence supporting their use in pediatric patients.

: For dermatologists reading this study, what do you think is the most important takeaway about how vitiligo is currently being treated in the real world, and where do you still see the biggest unmet needs for patients?

 The most important takeaway to me is that there are still clear gaps in vitiligo care and significant room to improve outcomes and quality of life in patients living with vitiligo. Across nearly 25,000 patients, about one in three diagnosed patients didn’t go on to receive treatment; those who were treated tended to stay on therapy only a few months, and treatment sequences varied widely. Those patterns held across age groups and disease extent, and are in line with other recent real-world analyses, providing a coherent picture of how vitiligo is being managed in the US today.

Overall, these findings highlight a lack of standardized approaches, and that current treatment approaches may not, in some patients, fully address patients’ long-term needs. Insights like these could help inform future research and clinical practice and, ultimately, potentially contribute to improving outcomes for people living with vitiligo.

Disclosures: Gauthier reported employment with Pfizer during the conduct of the study.

Sheikh A, Rafique W, Ali E. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology. Ann Med Surg (Lond). 2022 Aug 28;81:104499. 

Adiri R, Gauthier G, Hamzavi I, et al. Clinical Characteristics and Treatment Patterns in Patients With Vitiligo. JAMA Dermatol. 2026 Jul 1;162(7):720-725. 

Articles

Real-world US data from nearly 25,000 patients with vitiligo demonstrate substantial care gaps after diagnosis, despite frequent dermatology involvement. Approximately one-third received no treatment during follow-up, and those initiating therapy typically remained on first- or second-line regimens only two to four months, with highly variable sequencing. Facial involvement was common, reinforcing the likelihood of amplified psychosocial morbidity in visible disease. Age stratification showed pediatric patients predominantly managed with topical-only approaches, whereas adults more often received systemic therapies.

A JAMA study of nearly 25,000 vitiligo patients reveals major gaps in real-world treatment duration and consistency.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Real-World Data Reveal Gaps in Vitiligo Treatment, With Genevieve Gauthier, MSc

Matthew C. Breeggemann, MD is a nephrologist who cares for patients with kidney disease. He is medical director of UCSF's Kidney Stone Prevention Clinic, where he treats patients with a variety of kidney stone disorders in collaboration with the department of urology.

As a diverse collection of disorders with different underlying causes, genetic profiles, and rates of progression, 

 is highly heterogeneous and can be complicated to diagnose.

Matthew Breeggemann, MD, a nephrologist, assistant clinical professor in the Division of Nephrology, and medical director of the nephrology-based Kidney Stone Prevention Center at the University of California, San Francisco (UCSF), has faced his fair share of these patients with acute kidney injury, CKD, electrolyte disorders, and hypertension, noting the necessity of paying attention to all facets of disease management.

How a Nephrologist Diagnoses and Manages Chronic Kidney Disease

"You'll see patients where it's really straightforward, like diabetes, and you're pretty certain their kidney disease is due to diabetes. But you might have another patient with diabetes, hypertension, kidney stones, and other reasons they might have chronic kidney disease," Breeggemann told HCPLive in this interview. "It's about ensuring you're doing your due diligence as their clinician, their nephrologist or provider, and making sure you're not missing anything."

High blood sugar damages the nephrons over time

SGLT2 inhibitors, now standard first-line treatment for diabetic CKD

Finerenone, added on top of ACE/ARB and SGLT2 inhibitor therapy

Hypertension, glomerulonephritis, polycystic kidney disease, or structural blockages

Treatment targets the specific underlying cause of CKD

Varies by cause — e.g., ACE inhibitors/ARBs for hypertensive nephrosclerosis

Immunosuppressive therapy for autoimmune forms of glomerulonephritis (e.g., lupus nephritis)

Fast Facts: Diabetic CKD vs. Nondiabetic CKD

That diagnostic groundwork carries directly into how Breeggemann manages patients once a cause is identified, starting with the tools he relies on to pin down etiology in more complex cases.

"Our center also performs a substantial amount of genetic testing for kidney disorders, and these findings have definitely led to changes in how we approach and manage some patients with CKD," Breeggemann said.

Identifying disease-causing genetic variants in patients with CKD can support prognostication and personalized management, including nephroprotection strategies and decisions around kidney transplantation, and is also important for genetic counseling and reproductive family planning.

Genetic testing is often paired with tissue-level evaluation. "We also perform a high number of kidney biopsies, which can help determine the etiology of CKD, along with the degree of acute and chronic kidney damage," Breeggemann noted.

A kidney biopsy can be used even after a CKD diagnosis has already been made, to identify the exact root cause of damage, measure active inflammation against permanent scarring, and guide targeted treatment in ways standard blood and urine tests cannot.

Diagnostic testing, however, is only part of the picture. Breeggemann said his approach also weighs whether patients are able to follow through on treatment and what they themselves want out of care. "We also assess adherence to therapies," he said, pointing to barriers such as side effects, cost, and insurance approval that can get in the way even when a treatment plan is medically sound. Just as important, he said, is factoring in "the patient's priorities for their own care," to ensure management stays aligned with what patients themselves want.

Which Patients With CKD Need Closer Monitoring?

Asked which clinical values guide his treatment decisions in CKD, Breeggemann pointed to a single lab value used differently than many might expect.

"I'll lean on the eGFR a bit, but really I look at the trend," he explained.

A stable reading over time, even if abnormal, can be reassuring. "You might have a patient whose eGFR, based on a blood test like creatinine or, in some cases, cystatin C, is stable, say 50 milliliters per minute for the last 10 years," he said. "It's actually been really stable and well managed. It hasn't progressed at all."

The slope of that trend line, he said, can carry more clinical weight than the number itself. "You might have another patient whose eGFR was 50 a year ago and is now 25. It's decreased by a major degree, and those are patients you'll keep a much closer eye on through lab monitoring and appointments."

Beyond individual patient management, Breeggemann pointed to a systemic gap affecting CKD care broadly: the time it takes for new therapies to actually reach patients.

"Across medicine as a whole, it's quite interesting — it takes approximately 17 years following a new medical intervention or therapy to be routinely used in clinical practice," he said. "That seems like an incredibly long time, because it is, but it's probably best explained by the time needed to change clinical guidelines, disseminate information to clinicians, and change old habits among providers who are otherwise busy caring for hundreds or thousands of patients."

In CKD specifically, that lag is compounded by hurdles more specific to the disease: delayed diagnosis, delayed referral to a nephrologist, and communication gaps between primary care and the range of subspecialists who may share responsibility for a CKD patient's care.

"You can imagine how some of these patients might be seeing endocrinologists, nephrologists, cardiologists, and of course primary care," Breeggemann said. "We need to make sure who's going to prescribe the therapy, which often overlaps multiple fields." Patient buy-in, adherence, cost, and insurance coverage add further friction to getting new CKD therapies into routine use.

Even so, Breeggemann pointed to one factor working in favor of CKD patients: many newer CKD therapies are easier to stay on than the adoption timeline alone might suggest. "A lot of the therapies that we have available to us in nephrology, especially those aimed at reducing protein levels in patients with chronic kidney disease, generally are pretty well tolerated," he said.

Taken together, Breeggemann's account points to a broader pattern in CKD care: closing the gap between available therapies and everyday practice may depend as much on communication and coordination across specialties as on the science behind CKD treatment itself.

Editor’s Note: Breeggemann reports disclosures with Novo Nordisk.

Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk. 

2021;23(4):831-834. doi:10.1111/jch.14186

Knoers NVAM, van Eerde AM. The Role of Genetic Testing in Adult CKD. 

Journal of the American Society of Nephrology

2024;35(8):1107-1118. doi:10.1681/asn.0000000000000401


Videos

Matthew Breeggemann, MD, UCSF nephrologist, explains how CKD is diagnosed, monitored, and why new CKD therapies take years to reach patients.

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity

Triple hormone receptor agonism continues to advance obesity and diabetes care, with new phase 3 data suggesting retatrutide can drive substantial glycemic improvement alongside major weight loss in people with 

On a recent episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, reviewed topline results from the phase 3 TRIUMPH-2 trial evaluating retatrutide, a glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor triple agonist, in patients with type 2 diabetes.

Watch the full episode on the TRIUMPH-2 and TRIUMPH-3 data 

The trial enrolled roughly 1000 participants across 98 centers worldwide beginning in 2023, testing 4 mg, 9 mg, and 12 mg doses against placebo over 80 weeks. Weight loss proved dose-dependent, reaching up to 21% of body weight, with participants on the 12 mg dose losing an average of 23 kg from a baseline of 106 kg. Glycemic control improved in parallel, with A1C reductions of 1.4% to 1.6% compared with 0.2% in the placebo group.

The trial population entered with a mean A1C of 7.7%, a starting point closer to target than many incretin trials, which typically enroll patients nearer 9%. This finding echoes early data from the SURPASS program, where tirzepatide likewise produced pronounced A1C lowering in populations without markedly elevated baseline values, hinting the profile may extend to earlier-stage disease.

Discontinuation at the highest dose reached 14%, translating to 86% treatment continuation, a rate considered favorable given the magnitude of weight loss achieved. Investigators noted flexible titration strategies, including slower dose escalation and antiemetic support, can mitigate gastrointestinal tolerability issues seen across incretin-based therapies. Mandatory forced titration used in trial protocols contrasts with real-world practice, where clinicians often individualize dosing pace.

Collectively, the findings position retatrutide among the most potent agents yet studied for type 2 diabetes and obesity, with real-world dosing flexibility likely to shape adoption. The prospect of pairing dramatic weight loss with near-normalization of glycemic control has fueled interest in introducing triple agonist therapy earlier in the disease course, potentially blunting long-term complications.

Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.

Eli Lilly. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026. Accessed August 4, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional

In this segment from the latest episode of Diabetes Dialogue, cohosts Natalie Bellini, DNP, and Diana Isaacs, PharmD, discuss the topline results of the TRIUMPH-2 trial of retatrutide.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Daniela Ciciulla, APD, CEDC, MDiet, a PhD candidate at the University of Melbourne.

Possible Avoidant/Restrictive Food Intake Disorder (ARFID) occurs at similar rates in children with and without 

, a recent study found.¹ Many clinicians assume allergy-related dietary restriction raises eating-disorder risk, but the standard screening tool used in this study may still miss fear specific to food allergy.¹

In a population-based Australian birth cohort study, investigators followed 951 10-year-olds from the HealthNuts using the Eating Disorders in Youth Questionnaire (EDY-Q), including 102 with current, allergist-confirmed food allergy.¹ Possible ARFID prevalence was 23% (95% CI, 15-32) in children with food allergy and 21% (95% CI, 18-24) in those without (odds ratio [OR], 1.09; 95% CI, 0.67-1.80).¹ Because the EDY-Q does not capture fear of allergic reactions, investigators added a food allergy anxiety item, raising possible ARFID prevalence to 32% (95% CI, 24-42) among children with food allergy.¹

Possible ARFID inclusive of food allergy anxiety (ARFID-FAA) occurred more often in children with anaphylaxis (38% vs 26%) or an autoinjector prescription (36% vs 20%).¹ Current hay fever, not eczema or asthma, was linked to higher rates of both possible ARFID (27% vs 13%) and ARFID-FAA (40% vs 18%; 

Reported ARFID prevalence among children with food allergy has ranged widely, from 5% to 63%, across prior clinical samples, reflecting small cohorts, inconsistent screening instruments, and considerable risk of bias.¹ A 2024 meta-analysis pooled general-population ARFID prevalence at 4.51%, underscoring how far behind population-based estimates in food allergy cohorts remain.² Data directly comparing ARFID risk between children with and without food allergy in a general community sample have remained scarce until now.

Untreated ARFID carries nutritional, developmental, and psychosocial risk, reinforcing the need for a multidisciplinary approach combining dietetic and psychology expertise with allergy-specific clinical knowledge.¹ In the following Q&A, investigator Daniela Ciciulla, APD, CEDC, MDiet, a PhD candidate at the University of Melbourne, discusses the clinical implications for allergists integrating ARFID awareness into routine food allergy care.

Q&A: Possible Avoidant/Restrictive Food Intake Disorder (ARFID) occurs at similar rates in children with and without food allergy, a recent study found.¹ Many clinicians assume allergy-related dietary restriction raises eating-disorder risk, but the standard screening tool used in this study may still miss fear specific to food allergy.¹

Q&A: 1 in 5 Children with Food Allergy Screen Positive for Possible ARFID

 For allergists, what's the main clinical takeaway from this study on ARFID prevalence in children with food allergy?

 In our study, 10-year-old children completed the EDY-Q. This tool screens for common ARFID variants including fear of aversive consequences, lack of interest in food and/or sensory sensitivity. Our findings show 1 in 5 10-year-olds screen positive for being at risk of “possible ARFID,” suggesting it is a common problem.

A similar proportion of children with and without food allergy were identified as being at risk of possible ARIF. However, the EDY-Q may not be suitable to detect symptoms of ARFID in individuals with food allergy because it does not capture fear of aversive consequences specific to food allergy, such as fear of allergic reactions. We measured food allergy anxiety using an additional questionnaire, and when we included food allergy anxiety as a variant of ARFID, the prevalence of ARFID in children with food allergy was higher. 

 Your data show that overall ARFID prevalence was similar between children with and without food allergy, roughly 23% versus 21%. Was this surprising given the field's assumption that food allergy drives elevated ARFID risk?

 Previous research suggests that individuals with health conditions which require dietary management may be at increased risk of developing eating disorders. There is limited research on whether individuals with food allergy are more likely to have an eating disorder.

It is important to note that food allergy anxiety can occur without disordered eating or excessive dietary restriction. However, when food restriction or avoidance is associated with growth, nutrition or psychosocial compromise beyond that required food allergy management, referral to other services and assessment of ARFID risk, may be considered.

 Possible ARFID-FAA was notably higher among children with a history of anaphylaxis or an adrenaline autoinjector prescription. How should that inform which food allergy patients clinicians prioritize for closer feeding and mental health follow-up?

 Among children with current food allergy, we found that possible ARFID inclusive of food allergy anxiety (ARFID-FAA) occurred more often in children with a history of anaphylaxis or had been prescribed adrenaline autoinjectors, compared to those without. This trend wasn’t observed when we examined possible ARFID without considering food allergy anxiety. However, our study was not designed to determine whether these factors increase the risk of ARFID and further research is needed.

 Hay fever, more than eczema or asthma, was associated with higher ARFID and ARFID-FAA prevalence in your cohort. Do you have a hypothesis for why this particular comorbidity stood out?

 A large Swedish twin study found children with ARFID were more likely to have allergic conditions (allergic rhinitis, asthma, allergic gastroenteritis, allergic contact dermatitis and urticaria) than those without. It is possible that nasal congestion and loss of smell, associated with hay fever, may influence eating experiences in some children. More studies are needed to investigate the relationship between hay fever and the risk of ARFID.

 Given that no validated ARFID screening tool has yet been tested specifically for sensitivity in food allergy populations, what should clinicians do now when they suspect ARFID in a patient?

 The recognition and treatment for ARFID is multidisciplinary, ideally involving dietitians and psychologists with expertise in both food allergy and ARFID management. Our study was not designed to inform the clinical management of ARFID.

If there are concerns about restrictive eating beyond what would be expected for food allergy management, referral for further assessment should be considered. While not all children who report having symptoms of ARFID will meet diagnostic criteria, they may benefit from additional support. More research is needed to develop and validation of ARFID screening tools appropriate for clinical use in individuals with food allergy.

 What's your overarching message for the allergy community about integrating ARFID awareness into routine food allergy care?

 For children with food allergy, clinicians should remain alert to maladaptive eating behaviors that extend beyond what is necessary for safe allergen avoidance. If clinicians suspect maladaptive eating behaviors in their patients, referral to a multidisciplinary team for further assessment should be considered.

Ciciulla D, Koplin JJ, Yeo M, et al. Prevalence of Avoidant/Restrictive Food Intake Disorder (ARFID) in children with and without food allergy. 

Nicholls-Clow R, Simmonds-Buckley M, Waller G. Avoidant/restrictive food intake disorder: systematic review and meta-analysis demonstrating the impact of study quality on prevalence rates. Clin Psychol Rev. 2024;114:102502. 

Population-based data from 951 Australian 10-year-olds showed similar EDY-Q–defined possible ARFID prevalence in children with allergist-confirmed food allergy (23%) and without (21%; OR 1.09). Because EDY-Q omits fear of allergic reactions, adding a food-allergy anxiety item increased possible ARFID prevalence in food-allergic children to 32%. ARFID-FAA was more frequent with anaphylaxis history and autoinjector prescription, and hay fever correlated with higher ARFID and ARFID-FAA rates. Findings support multidisciplinary evaluation when restriction exceeds safe avoidance needs.

A study found children with and without food allergy screen positive for possible ARFID at similar rates, Daniela Ciciulla, APD, CEDC, says.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

1 in 5 Children with Food Allergy Screen Positive for Possible ARFID

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Reckitt announced US Food and Drug Administration (FDA) approval of Mucinex 12HR Cold & Fever Multi-Symptom on August 5, 2026, making it the first and only FDA-approved OTC cold and flu medication that treats fever, cough, chest congestion and body pain for 12 hours. The fixed-dose product contains guaifenesin, dextromethorphan hydrobromide, and naproxen sodium in a bilayer tablet.

The approval was granted through a new drug application (NDA), according to an August 5, 2026, press release from Reckitt, and marks the first OTC innovation in the cold and flu category in 14 years. The company described the decision as its first NDA approval under the Reckitt name and the fourth FDA approval involving the Mucinex product family.

 The product is now available through US retailers.

"True innovation starts with understanding consumer needs and applying science to solve them," said Angela Naef, PhD, Chief R&D Officer, Reckitt. "This approval is the culmination of more than a decade of research and development to create a first-of-its-kind formulation that delivers long-lasting relief from multiple cold and flu symptoms."

What Is Included in Mucinex 12HR Cold & Fever Multi-Symptom?

The formulation combines 3 active ingredients with distinct symptom-focused roles. Guaifenesin is an expectorant used to thin and loosen mucus, while dextromethorphan hydrobromide acts as a cough suppressant. Naproxen sodium, a nonsteroidal anti-inflammatory drug, is included for relief of fever and pain. The bilayer tablet provides immediate and extended release, according to the company.

Reckitt characterized the product as the first FDA-approved OTC cold and influenza medication combining these ingredients for up to 12 hours of multisymptom relief. This description reflects the company’s comparison with shorter-acting products and should not be interpreted as evidence of antiviral activity or reduced illness duration. The formulation is intended for symptomatic management.

Inflammatory responses associated with respiratory infections contribute to fever, pain, congestion, and other manifestations of the common cold and influenza.

 However, the relative contribution of individual pathways varies by infection and symptom. The newly approved combination does not treat the underlying viral infection, based on the indication described in the announcement.

Reckitt reported more than a decade of research, development, clinical evaluation, and regulatory engagement preceding the NDA approval.

The announcement also described the approval as the first OTC cold and influenza category innovation in 14 years. The regulatory action applies to symptom relief in the United States and does not establish efficacy for preventing influenza complications, transmission, hospitalization, or other infection-related outcomes.

"This milestone reinforces Reckitt's commitment to delivering trusted, science-backed solutions that meet everyday health needs and truly fit how Americans live," said Jérôme Lemaire, President, Reckitt North America. "By advan

ing the cold and flu category with longer-lasting, 12-hour symptom relief, we are not just expanding consumer choice and access, we are easing the care burden on families and empowering people to stay focused on their daily lives."

Reckitt. Reckitt announces US FDA approval of Mucinex 12HR Cold & Fever Multi-Symptom, the first OTC innovation in the cold & flu category in 14 years. Published August 5, 2026. 

https://www.prnewswire.com/news-releases/reckitt-announces-us-fda-approval-of-mucinex-12hr-cold--fever-multi-symptom-the-first-otc-innovation-in-the-cold--flu-category-in-14-years-302842875.html

Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718-725.

Reckitt received FDA approval via NDA for an OTC fixed-dose, bilayer tablet combining guaifenesin, dextromethorphan HBr, and naproxen sodium to provide up to 12-hour relief of fever, cough, chest congestion, and body pain. The product is positioned as a first-in-class OTC combination for prolonged multisymptom management and is now commercially available in US retailers. While development reportedly spanned more than a decade, no pivotal trial design details, efficacy endpoints, numerical outcomes, or safety event rates were disclosed. Labeling will clarify dosing, contraindications, and interaction risks.

The FDA approved a 12-hour OTC combination of guaifenesin, dextromethorphan, and naproxen for cold and influenza symptom relief.

FDA News

Influenza

The HCPLive influenza page is a resource for medical news and expert insights on the flu. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for influenza, and more.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom for OTC Use

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Tomashefski discusses where AATD diagnoses go missed and why APPs are positioned to close the gap.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Closing the AATD Diagnostic Gap, With Sarah Tomashefski, MSN

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the risks of ordering GLP-1 RAs online.

Secret Shopper Study Reveals GLP-1 Telehealth Gaps

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Centanafadine FDA approval, DT120 EMERGE trial results, and COMP360 psilocybin data headline this month's psychiatry coverage.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

3 Psychiatry Headlines You Missed in July 2026

Martina J. Porter, MD, is a dermatologist at Beth Israel Deaconess Medical Center.

STOP-HS1 and STOP-HS2 data show povorcitinib nearly doubled treatment response rates versus placebo in moderate to severe HS.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q&A: How STOP-HS Povorcitinib Data Impact Hidradenitis Suppurativa

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA

Hepatology

5 Hepatology Headlines You Missed in July 2026

Podcasts

This episode covers the recently announced topline data from the TRIUMPH-2 and TRIUMPH-3 phase 3 trials, as well as a study investigating online GLP-1 sales.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss

Highlights include an exploratory nerandomilast mortality analysis, the first North American bronchiectasis guideline from CHEST, and more.

Pulmonary Fibrosis

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

5 Pulmonology Headlines You Missed in July

The FDA has granted Fast Track designation to PVX108, Aravax's investigational peptide immunotherapy for peanut allergy, ahead of phase 2 data expected later in 2026.

Aravax's PVX108 Receives FDA Fast Track Designation for Peanut Allergy

Sibeprenlimab (Voyxact) achieves KDIGO goal, stabilizing eGFR decline in IgA nephropathy at 2-year Phase 3 VISIONARY readout. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Sibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN

One cytokine sits above the rest. Dr. Hanania explains why TSLP earns the label of master regulator, and why blocking it reaches inflammation that current therapies cannot.

Latest News

Real-World Data Reveal Gaps in Vitiligo Treatment, With Genevieve Gauthier, MSc

How a Nephrologist Diagnoses and Manages Chronic Kidney Disease

TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity

1 in 5 Children with Food Allergy Screen Positive for Possible ARFID

FDA Approves Mucinex 12HR Cold & Fever Multi-Symptom for OTC Use